US Patent 4,060,691: Misoprostol Compound Claims, Expiration, and Patent Landscape

US Patent 4,060,691 is the foundational U.S. compound patent covering misoprostol and closely related prostaglandin E1 analogs. It was assigned to G.D. Searle & Co. and issued on November 29, 1977. Its original 17-year patent term expired on November 29, 1994. The patent no longer creates an enforceable U.S. barrier to generic misoprostol, although its claims remain relevant for historical claim scope, freedom-to-operate analysis, and interpretation of later prostaglandin patents.[1]

The pasted claim text omits the chemical structure drawings for claims 1 and 2. The available language nevertheless identifies the patent as a compound patent directed to substituted prostaglandin analogs, including the compound now known as misoprostol.

What drug and chemical structure does US Patent 4,060,691 cover?

The patent covers prostaglandin analogs having a cyclopentanone core, a heptanoate side chain, and a hydroxy-methyl-substituted octenyl side chain.

The key compound in the claims is:

Methyl 7-[(3(R)-hydroxy-2β-(4(S)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-5-oxocyclopent-1α-yl)]heptanoate

This compound is a stereochemically defined form of misoprostol. Misoprostol is a synthetic prostaglandin E1 analog marketed primarily for prevention of NSAID-induced gastric ulcers. It is also used in obstetric and gynecologic indications, including cervical ripening, medical abortion, and management of postpartum hemorrhage, subject to applicable regulatory and clinical protocols.[2]

Core structural elements

Structural element	Patent significance
Cyclopentanone ring	Defines the prostaglandin-type pharmacophore
3(R)-hydroxy substituent	Establishes ring stereochemistry
2β-substituted side chain	Connects the ring to the hydroxy-methyl octenyl group
4-hydroxy-4-methyl-trans-1-octenyl group	Defines the distinctive misoprostol side chain
Methyl heptanoate	Forms the terminal ester portion of the molecule
Protected hydroxyl groups	Covered through lower alkanoyl, tetrahydropyranyl, and related derivatives in the broader claim language

What does claim 1 of US Patent 4,060,691 cover?

Claim 1 is the broad genus claim. Based on the supplied text, it covers a class of prostaglandin analog compounds in which:

R1 is hydrogen or lower alkyl;
R2 and R3 may be hydrogen;
R2 and R3 may be lower alkanoyl groups;
R2 and R3 may be tetrahydropyran-2-yl protecting groups;
R2 and R3 may be tri-lower-alkylsilyl groups, based on the truncated phrase in the supplied transcription.

The full claim depends on a chemical structure drawing that is missing from the pasted text. The substituent definitions indicate that claim 1 was drafted to cover both final active compounds and protected intermediates used in their synthesis.

Functional scope of claim 1

Claim 1 likely reaches three commercially relevant categories:

The unprotected prostaglandin analogs, where the hydroxyl groups are hydrogen-substituted.
Esterified or otherwise protected derivatives, including acetyl-type lower alkanoyl derivatives.
Tetrahydropyranyl and trialkylsilyl derivatives used as synthetic intermediates or prodrug-like analogs.

The use of protecting groups broadens the claim beyond the final pharmaceutical ingredient. A compound could fall within claim 1 even if it is not the marketed form, provided the underlying ring and side-chain structure and the specified substituent options are present.

Because the chemical drawing is absent, a definitive element-by-element infringement opinion cannot be based solely on the pasted text. The claim language supports a broad genus interpretation, but the exact ring substitution pattern must be read from the issued patent.

What does claim 2 cover?

Claim 2 narrows claim 1 through a second formula and limits R4 to a lower alkyl radical.

The claim appears directed to an esterified subset of the broader prostaglandin analog genus. Its commercial relevance is greater than that of claim 1 because the marketed misoprostol structure contains a methyl ester.

The principal narrowing feature is the lower alkyl ester or related lower-alkyl substituent represented by R4. Typical lower alkyl groups in this type of patent drafting include methyl, ethyl, propyl, and butyl, although the exact interpretation depends on the formula and specification.

Claim 2 therefore appears to function as an intermediate species claim between:

the broad compound genus in claim 1; and
the specifically identified misoprostol compounds in claims 3 through 5.

What does claim 3 cover?

Claim 3 covers the specific stereochemically defined compound:

Methyl 7-[(3(R)-hydroxy-2β-(4(S)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-5-oxocyclopent-1α-yl)]heptanoate.

The claim identifies:

a methyl ester;
a 3(R)-hydroxy configuration on the cyclopentanone ring;
a 2β side-chain orientation;
a 4(S) configuration in the hydroxy-methyl octenyl side chain;
a trans double bond;
a 5-oxo cyclopentane ring.

This is a narrow composition-of-matter claim. A compound lacking one of these required stereochemical or structural elements would not literally satisfy claim 3, although it could potentially fall within claim 1 or claim 2 if those claims were construed more broadly.

What does claim 4 cover?

Claim 4 covers the racemic form of the methyl ester compound.

The claim is narrower than the broad genus claim but broader than claim 3 with respect to stereochemical purity. It is directed to a racemic material containing both enantiomeric forms at the relevant stereocenter.

The distinction between claims 3 and 4 is important:

Claim	Stereochemical scope
Claim 3	Defined stereoisomer, including the 4(S) side-chain configuration
Claim 4	Racemic form of the specified compound
Claim 5	4(RS) side-chain configuration, indicating a racemic or mixed stereochemical form

A racemate can infringe a claim directed expressly to the racemic compound even when neither enantiomer alone is present as the commercial product. Conversely, a single stereoisomer may avoid a racemate-specific claim while still falling within a broader genus claim.

What does claim 5 cover?

Claim 5 covers:

Methyl 7-[(3(R)-hydroxy-2β-(4(RS)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-5-oxocyclopent-1α-yl)]heptanoate.

The notation “4(RS)” indicates that the side-chain center is not limited to one absolute configuration. The claim therefore reaches material containing the R and S configurations, either as a racemic mixture or as an unresolved stereochemical mixture, depending on the specification’s terminology.

Claims 4 and 5 are related but not necessarily identical in scope. Claim 4 expressly characterizes the compound as racemic. Claim 5 uses the RS descriptor in the molecular name. In a litigation setting, the specification, prosecution history, and accepted nomenclature would determine whether the claims cover the same commercial stereochemical composition or distinct stereochemical definitions.

When did US Patent 4,060,691 lose exclusivity?

The patent’s original U.S. patent term ended on November 29, 1994, 17 years after issuance.[1] The patent issued before the United States changed to a patent term measured principally from the nonprovisional filing date.

Event	Date
U.S. patent issued	November 29, 1977
Original statutory term	17 years from issue
Original expiration	November 29, 1994
Current enforceability	Expired
Current composition-of-matter exclusivity	None

There is no current patent-term barrier based on US 4,060,691. A patent that has expired can remain relevant to historical patent landscaping, prior-art analysis, and claim interpretation, but it cannot support a new infringement action for post-expiration activity.

What is the FDA and Orange Book status of misoprostol?

Misoprostol was approved by the FDA as Cytotec under NDA 019268. The approved product is an oral tablet available in 100 microgram and 200 microgram strengths.[2]

The original compound patent expired before the current generic market developed. Misoprostol is available through generic approvals, and the expired patent does not provide current Orange Book exclusivity.

Regulatory issue	Status
Active ingredient	Misoprostol
Drug class	Prostaglandin E1 analog
Reference product	Cytotec
Original sponsor	G.D. Searle & Co.
FDA dosage forms	Oral tablets
Common strengths	100 mcg and 200 mcg
Original NDA	019268
Compound patent	US 4,060,691
Patent status	Expired
Current Orange Book barrier from this patent	None
Biosimilar pathway	Not applicable

Misoprostol is a small molecule, not a biologic. Biosimilar litigation and the Biologics Price Competition and Innovation Act pathway therefore do not apply. Competition proceeds through the ANDA generic pathway rather than a 351(k) biosimilar application.

What formulation patents protect Cytotec or generic misoprostol?

US 4,060,691 is principally a compound patent. The supplied claims do not create a broad tablet formulation claim covering excipients, dissolution profiles, dosage uniformity, or packaging.

A formulation patent would generally require limitations such as:

a defined misoprostol concentration;
a particular tablet matrix;
stabilizers or excipients;
a specified dissolution profile;
moisture protection;
manufacturing conditions;
or a method of maintaining potency.

The quoted claims do not contain those limitations. They cover chemical compounds and stereochemical variants rather than a commercial tablet architecture.

Any historical formulation or manufacturing patents would need to be analyzed separately by patent number and claim language. They would not automatically extend the life of the compound claims in US 4,060,691.

Does US 4,060,691 contain method-of-use claims?

The claims supplied are composition claims. They do not claim:

treatment of gastric ulcer disease;
prevention of NSAID-induced ulcers;
cervical ripening;
labor induction;
medical abortion;
postpartum hemorrhage treatment;
or any other therapeutic method.

This distinction has commercial significance. The patent could have blocked manufacture or sale of a claimed compound during its term regardless of the labeled use. After expiration, it no longer blocks generic manufacture. Separate method-of-use patents, if any existed, would require independent analysis and would not be extensions of the compound claims.

Were there Paragraph IV challenges to US 4,060,691?

A Paragraph IV certification is relevant only while a listed patent remains unexpired and is listed in the Orange Book as a patent that would be infringed by the proposed ANDA product.

Because US 4,060,691 expired in 1994, it is not a current Paragraph IV barrier. Generic applicants could rely on patent expiration rather than challenge an enforceable patent through a present-day Paragraph IV case.

The commercial entry risk associated with this patent is therefore historical. The relevant legal event was expiration, not a continuing patent challenge.

What patent litigation affects misoprostol?

US 4,060,691 no longer supports a viable infringement case. No current litigation risk arises from its compound claims.

Historical disputes involving misoprostol could still concern:

patent term and expiration;
generic approval timing;
formulation patents;
manufacturing processes;
trademark rights in Cytotec;
or use-related regulatory issues.

Those issues are legally separate from the expired composition claims. A company assessing current U.S. entry would focus on live patents listed for the reference product, regulatory exclusivity, product liability, manufacturing controls, and any non-Orange Book patents directed to a specific formulation or process.

How strong is the patent estate for misoprostol?

The original compound estate was strong during its enforceable term because claims 3 through 5 identified the active pharmaceutical structure and its stereochemical variants. Composition-of-matter claims generally provide the broadest exclusionary leverage against competing manufacturers.

Its current strength is zero from an enforcement perspective because the patent expired.

Estate component	Historical strength	Current status
Broad compound genus	High	Expired
Specific misoprostol compound	Very high	Expired
Racemic compound	High	Expired
Stereochemical variants	High	Expired
Tablet formulation	Not established by supplied claims	Requires separate review
Method of use	Not present in supplied claims	Requires separate review
Manufacturing process	Not established by supplied claims	Requires separate review
Biosimilar protection	Not applicable	Not applicable

How does misoprostol compare with competing prostaglandin products?

Misoprostol competes with several prostaglandin and prostaglandin-analog products, but the competitive set differs by indication.

Product	Active ingredient	Principal use area	Regulatory pathway
Cytotec and generics	Misoprostol	Gastric-ulcer prevention; obstetric use	Small-molecule NDA/ANDA
Cervidil	Dinoprostone	Cervical ripening	Small-molecule drug
Prepidil	Dinoprostone	Cervical ripening	Small-molecule drug
Hemabate	Carboprost tromethamine	Postpartum hemorrhage and abortion-related indications	Small-molecule drug
Mifeprex combination regimens	Mifepristone with misoprostol	Medication abortion	Small-molecule drugs
Lubiprostone	Lubiprostone	Constipation and IBS-C	Later-generation prostaglandin-related compound

Misoprostol has a lower current patent barrier than newer products because its foundational composition claims expired decades ago. Its commercial defenses are more likely to involve manufacturing scale, regulatory compliance, supply reliability, product quality, and distribution rather than patent exclusivity.

What generic launch risks exist today?

A generic misoprostol entrant faces limited risk from US 4,060,691 itself. The relevant risk categories are:

FDA approval and bioequivalence requirements.
Product quality and stability, particularly because misoprostol is sensitive to degradation.
Manufacturing controls for low-dose tablets.
Labeling restrictions and indication-specific regulatory requirements.
Supply-chain reliability.
Any later patents directed to a particular formulation, dosage regimen, device, or manufacturing process.
Trademark and trade dress restrictions associated with Cytotec.

There is no biosimilar risk, no live compound patent risk from US 4,060,691, and no current exclusivity created by claims 1 through 5.

Key Takeaways

US 4,060,691 is the foundational compound patent for misoprostol and related prostaglandin analogs.
Claim 1 is a broad genus claim covering substituted and protected prostaglandin compounds.
Claim 2 narrows the genus to a lower-alkyl-substituted or esterified subset.
Claims 3 through 5 cover specific stereochemical, racemic, and mixed-stereochemistry forms of the misoprostol structure.
The patent issued on November 29, 1977, and expired on November 29, 1994.
The patent contains composition claims, not the method-of-use claims described in the question’s therapeutic indications.
It is not a current Orange Book or Paragraph IV barrier.
Misoprostol is a small molecule, so biosimilar law does not apply.
Current commercial risk is more likely to arise from formulation, process, regulatory, quality, and supply issues than from the expired compound patent.

FAQs

Is misoprostol still protected by a U.S. composition patent?

No. The foundational composition patent, US 4,060,691, expired in 1994.

Does US 4,060,691 cover both pure misoprostol stereoisomers and racemic material?

The claims cover specifically identified stereoisomers as well as racemic or RS-defined forms. The exact overlap depends on the structural formula and claim construction.

Can a company manufacture generic misoprostol after expiration of US 4,060,691?

Yes, subject to FDA approval, applicable regulatory requirements, and any separate unexpired patents directed to a particular formulation, process, dosage regimen, or product configuration.

Is misoprostol subject to biosimilar competition?

No. Misoprostol is a chemically synthesized small molecule. Generic competition proceeds through the ANDA framework, not the biosimilar pathway.

Does the patent cover Cytotec tablets as a formulation?

The supplied claims do not claim a tablet formulation. They claim chemical compounds. Separate formulation patents would have to be evaluated independently.

References

U.S. Patent No. 4,060,691. (1977). Prostaglandin analogs. U.S. Patent and Trademark Office. https://patents.google.com/patent/US4060691
U.S. Food and Drug Administration. (n.d.). Cytotec (misoprostol) tablets prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Code, Title 35, § 154. (n.d.). Contents and term of patent; provisional rights. https://uscode.house.gov/
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
South Africa	75/1391	Mar 6, 1975

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	207355	⤷ Start Trial
Austria	351684	⤷ Start Trial
Austria	A227375	⤷ Start Trial
Australia	7947175	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,060,691

Summary for Patent: 4,060,691